Maharashtra haemophilia patients face medicine shortages, forcing travel to Gujarat for treatment, risking health and ...

Karimnagar: The Haemophilia Society Peddapalli Chapter organised a Continuing Medical Education (CME) programme and ...

A long-acting Factor VIII replacement therapy for haemophilia A from Sobi and Sanofi has been recommended for use by the NHS ...

Sobi’s Sanofi-partnered Altuvoct (efanesoctocog alfa) has been recommended by the National Institute for Health and Care ...

An estimated 7700 people in England have haemophilia A, with around 1900 classified as severe cases where their factor VIII activity level is less than 1%. Current treatments involve factor VIII ...

"Louie had a series of blood tests a few weeks later and we were told he had severe haemophilia,” the mum, a marketing consultant from the Isle of Wight," Rosie said. “We were completely ...

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low demand and interest. A Pfizer spokesperson told Pharmaceutical Technology in ...

Haemophilia, a genetic disorder characterised by deficient clotting factors, often leads to musculoskeletal complications such as haemophilic arthropathy. These complications result in reduced ...

The Infected Blood Inquiry said it will publish a further report looking at the adequacy of the Government’s approach to compensation.

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...